Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2 gene-transfected KB cells
- Development stage
- Unknown
- Lead developer
- Yokohama City University
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Gene Therapies
- Administration
- Subcutaneous, Intratumoral
01
Overview
**IL-2 gene-transfected KB cells** are a form of therapeutic cancer vaccine created by genetically modifying human KB carcinoma cells (a cell line derived from oral squamous cell carcinoma) to express and secrete interleukin-2 (IL-2). These modified cells are typically irradiated to prevent proliferation and then administered as a form of autologous or allogeneic cell-based immunotherapy. The therapeutic principle is that localized IL-2 secretion by the modified tumor cells stimulates a strong antitumor immune response, activating cytotoxic T lymphocytes and natural killer (NK) cells against the tumor, and potentially establishing tumor-specific immunological memory. This approach is an experimental form of gene therapy and cancer immunotherapy primarily evaluated in preclinical settings and early-phase clinical trials, with particular application in head and neck squamous cell carcinoma.
- Other names
- KB/IL-2 cellsKB/hIL-2 cellsinterleukin-2 gene-modified KB cellsinterleukin2 gene-modified KB cellsinterleukin 2 gene-modified KB cellsIL2G-KBIL-2G-KBIL 2G-KB
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on IL-2 gene-transfected KB cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2 gene-transfected KB cells.